---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-008665"
form_type: "8-K"
ticker: "STIM"
cik: "0001227636"
company_name: "Neuronetics, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:18:14.137559+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Neuronetics Q1 revenue $15.5M (+10% YoY); narrows FY revenue guidance to $68-73M

## Summary
- Net loss of $(10.5)M or $(0.38)/share vs $(10.8)M or $(0.41)/share in Q1 2022.
- U.S. treatment session revenue rose 12% to $10.6M; shipped 49 NeuroStar systems.
- Full-year 2023 revenue guidance set at $68-73M; Q2 2023 revenue expected $17-18M.
- Amended SLR credit facility provides up to $60M at SOFR+5.65%, interest-only until March 2026.
- United Healthcare and BCBS of Mississippi updated policies to allow NPPs to prescribe TMS.

## SEC filing metadata
- accession: 0001558370-23-008665
- form_type: 8-K
- ticker: STIM
- cik: 0001227636
- company_name: Neuronetics, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1227636/000155837023008665/0001558370-23-008665-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1227636/000155837023008665/stim-20230509x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-008665
- JSON: https://secwatch.observer/filing/0001558370-23-008665.json
- Plain text: https://secwatch.observer/filing/0001558370-23-008665.txt

## Key facts
- Earnings Releases
  Neuronetics, Inc. reported the three months ended March 31, 2023 results: revenue $15.5 million, net income $(10.5) million, EPS $(0.38) per share.
  - Period: the three months ended March 31, 2023
  - Revenue: $15.5 million
  - Net income: $(10.5) million
  - EPS: $(0.38) per share
  - Result: reported results
  source text: therapies in the world, today announced its financial and operating results for the first quarter of 2023. First Quarter 2023 Highlights ● First quarter 2023 revenue of $15.5 million, an increase of 10% over the first quarter of 2022 ● U.S. treatment session revenue increased 12% over the first quarter of 2022 ● Shipped 49 systems continuing our capital
  evidence_url: https://www.sec.gov/Archives/edgar/data/1227636/000155837023008665/0001558370-23-008665-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.